Centro Médico Teknon (Quirón Salud), Barcelona, Spain.
J Diet Suppl. 2023;20(1):1-14. doi: 10.1080/19390211.2021.1944947. Epub 2021 Jul 5.
To assess the effectiveness of a food supplement (Tinnitan Duo®) containing 5-hydroxytryptophan, , magnesium, melatonin, vitamin B5 and B6, and zinc at improving tinnitus response and intensity. Prospective, single-center interventional study including patients with subjective tinnitus and emotional affectation. The primary endpoint was the change in the Tinnitus Handicap Inventory (THI) total score and the emotional subscale after 3 months of treatment. Secondary endpoints were the change from baseline to month 3 in (1) the Tinnitus Distress Rating (TDR) scale, and (2) in hearing status, and the safety profile of patients throughout the study. Sixty-one patients were included, and 29 completed the study. The THI total score was significantly reduced after 3 months of treatment in the per-protocol (PP, all the patients with no major protocol deviations) and intention-to-treat (ITT) populations (-15.7 and -7.5, respectively; = 0.001). The emotional subscale score significantly decreased after 3 months of treatment by -5.6 in the PP ( = 0.001) and by -2.6 in the ITT populations ( = 0.001). Perceived tinnitus loudness significantly decreased after 3 months of treatment ( = 0.001). The audiogram showed no significant changes in hearing status after 3 months of treatment. Of the five adverse events (AEs) reported, all were mild or moderate, and three were related to the study treatment (two headaches and one dizziness). This new food supplement was associated with an improved tinnitus-related emotional affectation and with a good safety profile.
评估一种含有 5-羟色氨酸、镁、褪黑素、维生素 B5 和 B6 以及锌的食品补充剂(Tinnitan Duo®)对改善耳鸣反应和强度的效果。这是一项前瞻性、单中心干预性研究,纳入了有主观性耳鸣和情绪影响的患者。主要终点是治疗 3 个月后耳鸣残疾量表(THI)总分和情绪亚量表的变化。次要终点是从基线到第 3 个月时(1)耳鸣困扰量表(TDR)评分的变化,以及(2)听力状况的变化,以及整个研究过程中患者的安全性概况。共纳入 61 例患者,其中 29 例完成了研究。在方案人群(PP,无主要方案偏差的所有患者)和意向治疗人群(ITT)中,THI 总分在治疗 3 个月后显著降低(分别为-15.7 和-7.5, = 0.001)。在 PP 中,情绪亚量表评分在治疗 3 个月后显著降低(-5.6, = 0.001),在 ITT 人群中降低(-2.6, = 0.001)。治疗 3 个月后,患者对耳鸣的感知响度显著降低( = 0.001)。听力状况的听力图在治疗 3 个月后没有显示出显著变化。报告的 5 起不良事件(AE)中,所有均为轻度或中度,其中 3 起与研究治疗有关(2 起头痛,1 起头晕)。这种新的食品补充剂与改善与耳鸣相关的情绪影响有关,并且具有良好的安全性概况。